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Stereotactic Synchrotron Radiotherapy (SSRT) and Microbeam Radiation Therapy (MRT) are both
novel approaches to treat brain tumor and potentially other tumors using synchrotron radiation.
Although the techniques differ by their principles, SSRT and MRT share certain common aspects with
the possibility of combining their advantages in the future. For MRT, the technique uses highly
collimated, quasi-parallel arrays of X-ray microbeams between 50 and 600 keV. Important features of
highly brilliant Synchrotron sources are a very small beam divergence and an extremely high dose
rate. The minimal beam divergence allows the insertion of so called Multi Slit Collimators (MSC) to
produce spatially fractionated beams of typically ~25e75 micron-wide microplanar beams separated
by wider (100e400 microns center-to-center(ctc)) spaces with a very sharp penumbra. Peak entrance
doses of several hundreds of Gy are extremely well tolerated by normal tissues and at the same time
provide a higher therapeutic index for various tumor models in rodents. The hypothesis of a selective
radio-vulnerability of the tumor vasculature versus normal blood vessels by MRT was recently more
solidiﬁed.
SSRT (Synchrotron Stereotactic Radiotherapy) is based on a local drug uptake of high-Z elements in
tumors followed by stereotactic irradiation with 80 keV photons to enhance the dose deposition only
within the tumor. With SSRT already in its clinical trial stage at the ESRF, most medical physics problems
are already solved and the implemented solutions are brieﬂy described, while the medical physics as-
pects in MRT will be discussed in more detail in this paper.
© 2015 Published by Elsevier Ltd on behalf of Associazione Italiana di Fisica Medica. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ax: þ33 (0) 476882020.
alf of Associazione Italiana di Fisica Medica. This is an open access article under the CC BY-NC-ND license (http://
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The different contributions within the COST SYRA3 Action in this
special issue highlight the history of the development of two new
radiotherapies; MRT and SSRT, and their future potential medical
applications. The phase I clinical trials in SSRT have allowed the
community to move forward with synchrotron based therapies in
particular from a safety point of view, requiring the implementa-
tion of a small hospital-like environment at the biomedical beam-
line ID17 at the European Synchrotron Radiation Facility (ESRF) in
Grenoble, France. This milestone also helps to solve some of the
medical physics aspects in MRT which are particularly challenging
due to the microscopically small sizes of the beams and the very
high dose rates. This high dose gradient requires accurate mea-
surements of dose in microscopic volumes, something which is not
necessary in standard radiotherapy. Despite the increasing
computing power, Monte Carlo (MC) calculations in such small
volumes for MRT applications are still time consuming and a
recently developed solution using a convolution based algorithm
now allows fast dose calculations from CT data to make a treatment
plan. Dose measurements in MRT are difﬁcult not only due to the
demands on the spatial resolution but equally from the high dose
rates used which are in the range of 8e16 kGy/s. Additionally, the
low energy photons may require an important correction since the
response of commonly used radiation detectors shows important
variations for low energy X-ray photons.
Medical physics aspects in SSRT
The ﬁrst clinical study of therapeutic applications of Contrast-
Enhanced Synchrotron Stereotactic Radiation Therapy (SSRT) has
been underway since June 2012 at the (ESRF) and at the Uni-
versity Hospital (CHU) in Grenoble (France). This phase I-II
clinical trial is designed to test the feasibility and safety of SSRT
through a dose escalation protocol. Two years after the start of
the trial, this study has already included eight patients suffering
from brain metastases of medium-to-small volume. Preclinical
studies [1,2], based on the original work of Norman [3] had
highlighted the potential of the technique and motivated this
clinical trial. The treatment at the ESRF is based on stereotactic
irradiations using high-ﬂux, quasi-parallel, monochromatic me-
dium energy X-ray beams (80 keV). The irradiation is performed,
in the presence of an iodinated contrast agent, which previously
was introduced into the tumor. At these energies, a localized
dose enhancement occurs in the target, due to an increased
photoelectric absorption of X-rays. This local increase in dose is
due to the difference in the photon interaction mechanisms in
the target volume where the contrast agent leaks from the
capillaries when compared to the healthy brain where the iodine
concentration remains negligible. The moderate kinetic energy of
the photoelectrons and the iodine Auger electrons is deposited
over a micrometer distance with a maximum distance of tens of
micros, in the close vicinity of the heavy atoms; whereas
Compton scattering predominates in the surrounding healthy
tissues. Despite a strong falloff of the percentage depth dose
(PDD) using 80 keV photons, a favorable dose deposition can be
achieved at the tumor with better tissue sparing when compared
to Co-60 irradiations using the same number of ports, thus
generating interest for treating deep seated tumors.
A dedicated treatment room has been built at the ESRF medical
beamline [4]. The patient is installed on an armchair with his or her
head tightly maintained by the same stereotactic frame used at the
CHU for complimentary irradiations. The current dosimetry proto-
col in SSRT usesmonochromatic X-rays at 80 keVwith a dose rate of
~1 Gy/s which is slightly higher but in the same order of magnitudelike typical dose rates at the clinic. The speciﬁcity comes from the
use of a 2 mm high beam, requiring the regular scanning through
the beam to obtain a homogenous coverage of the tumor volume to
be irradiated. A dedicated treatment planning system (TPS) was
adapted to SSRT. The synchrotron beamline geometry was modeled
and included as a phase space ﬁle in the TPS. The dosimetry is based
on parallelized Monte Carlo simulations of low to medium energy
electrons and polarized photon transport in presence of high-Z
material [5]. Dedicated quality assurance protocols were imple-
mented. An absolute dosimetry protocol was adapted according to
the gold standard used in conventional RT [6]. The treatment plans
and absolute dosimetry are validated with measurements per-
formed in a dedicated water tank as well as in solid water with and
without bone slabs. A 2D dosimetry technique is being developed in
anthropomorphic phantoms using EBT3 Gafchromic ﬁlms.
The contrast agent uptake has been previously studied on 12
patients who received an intravenous bolus of iodinated contrast
agent (40 mL, 4 mL/s), followed by a steady-state infusion (160 mL,
0.5 mL/s) in order to ensure stable intratumoral amounts of iodine
during the treatment. Absolute iodine concentrations and quanti-
tative perfusion maps were derived from 40 multi-slice dynamic
conventional CT images of the brain (recruitment day) or from
quantitative synchrotron radiation CT (treatment day). For three of
these patients, iodine concentrations reached in the tumor were
compared between the recruitment day and the treatment day (~10
days interval). The post-infusion mean intratumoral iodine con-
centration (over 30 min) reached 1.94 ± 0.12 mg/mL (200 mL of
contrast injected) [7].
In this ﬁrst clinical trial phase, the patients receive a fraction of
their overall treatment by SSRT (5 Gy), while the remaining of the
treatment is delivered by standard stereotactic irradiation at the
CHU (6 Gy and 2  11 Gy). All patients were in good general con-
dition [8]. Future developments in medical physics for SSRT are
expected to include in invivo dosimetry and static irradiations using
minibeams [9].
In vivo dosimetry based on optically stimulated luminescence
(Al2O3 crystals) has already been tested on one patient [10] but
requires a complex set-up and ofﬂine reading. A new in vivo
dosimetry protocol is currently being developed, based on 2D
entrance and exit ﬂuence measurements using dedicated pixelated
transmission detectors. The dose retrieval will be performed using
inverse problem methods (iterative reconstruction of the dose)
adapted to local and limited projection tomography problems [11].
The monochromatic minibeam technique is being developed in
parallel to further improve the normal tissue sparing effect and
simplify some of the delicate safety issues because of the lower
dose rate. The ﬁrst experiments in monochromatic Minibeam Ra-
diation Therapy (MBRT) (600 mm-wide beams, 1200 mm ctc)
conﬁrmed that this technique keeps (part of) the sparing tissue
capability observed in the thinner microbeams, while signiﬁcant
tumor growth delay was still observed [12]. The next development
is the transfer of this technique to clinical trials I in order to be able
to perform the SSRT dose escalation protocol to its end maintaining
a suitable bone radiation tolerance [13].
The non-homogenous dose distribution due to the irregular
uptake in the tumor environment of the dose enhancing drug leads
to in-homogeneities, which may complicate the interpretation of
the outcome of the treatment [7]. The contrast agent, moreover,
remains extracellular and is not optimal for dose enhancement at
the cellular and molecular levels with respect to the DNA. An
interesting perspective would be to inﬂuence importantly the
microscopic dose distribution fromAuger electrons through photon
activation processes [14] or from optimized radio-chemotherapy
protocols [15], which would more selectively damage the tumor
cells with non-repairable double strand breaks.
Figure 1. PVDR for different ﬁeld sizes and center-to-center spacings.
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inputs relating to knowledge about the microscopic drug distri-
bution to be assumed. This may be another important avenue to be
fostered within the current COST SYRA3 action to improve the local
dose deposition within the tumor cell. Such dose enhancement
should be better understood and warrant microdosimetry studies.
Adequate Monte Carlo calculations are used to predict such local
dose distributions and cover an entire research ﬁeld on its own.
However, results from such research efforts could be best exploited
and tested on the ID17 biomedical beamline through preclinical
studies using tunable monochromatic X-rays, before being trans-
ferred to clincial trials.
Theoretical dose calculations in microbeam radiation therapy
The ﬁrst Monte Carlo calculations in MRT go back to 1992, when
Dan Slatkin [16] calculated dose distributions produced inside a
human-head phantom. The use of “cylindrical” (circular) beams
was initially very attractive, since much higher values in PVDR
(Peak to Valley Dose Ratios) could be achieved. Most preclinical
research during the last 25 years has been performed with micro-
planar beams [17e19], due to the ease of manufacturing collimators
which produce planar beams. Early MC calculations beneﬁted from
advanced physics models [20]. E. A. Siegbahn [21] compared several
MC codes, including PENELOPE, GEANT and the improved EGSnrc
version, which were determined to be adequate codes for dosi-
metric studies in MRT due to their advanced low energy electron
and photon tracking libraries. The issue of polarization was ﬁrst
studied by Felici and Hugtenburg [22,23]. I. Rovira-Martinez used a
more recent version of PENELOPE including the polarization and
incorporated a phase space ﬁle (PSF) from the speciﬁc geometry at
the ESRF [24]. A ﬁnal and comprehensive analysis of all important
parameters like PSF, polarization and residual leakage radiation
from the tungsten carbide MSC was published by Bartzsch
et al.[25]. A possible improvement to the MC calculations might be
the inclusion of the totally reﬂected photons interacting at grazing
angles with the inner surface of the tungsten carbide MSC, which
may lead to a small dose contribution of photons from that surface
into the valley area. Their contribution can be estimated to be lower
than 5% of the calculated valley dose. The most important progress
and mandatory step to move forward with the proposed veterinary
trials was the development of a fast TPS. A convolution based al-
gorithm was introduced by Bartzsch [26] and implemented in the
VIRTOUS platform [87]. In addition, the platform also allows a full
MC calculation with microbeams of different sizes and center-to-
center (ctc) distances inside a phantom or a patient with existing
CT data from a commercial unit, previously calibrated for the cor-
rect conversion in Hounsﬁeld Units (HU).
The peak-to-valley dose ratio (PVDR) is a relative value, and
consequently becomes important only when dose values are con-
verted from the treatment plan to compute the absolute valley dose
for the normal tissue, which corresponds to the classical maximum
admissible dose value with respect to normal tissue complications.
The strong inﬂuence of larger ﬁeld sizes and tighter ctc spacing
rapidly leads to very small PVDRs as shown in Fig. 1. Unpublished
data by Laissue et al. indicate that for microbeam sizes between
25 microns and 75 microns FWHM, the adverse effects or normal
tissue complications do only correlate with the valley dose and not
with the peak dose. On the other side, preclinical studies did show,
that a narrow microbeam ctc spacing is more effective for tumor
growth suppression than a wide microbeam [27,28]. Comparable
geometries were used; e.g. 50 micronwidth and 200 ctc versus 500
microns width and 2000 microns ctc, in order to keep the ratio of
the direct cell killing from high peak doses in the unit volume
constant. In this context it should be pointed out that several of theMRT-speciﬁc effects are related to the surface area between high
and low dose regions and the contact surface is certainly instru-
mental for the repair of heavily irradiated tissues in the peak
regions.
From a theoretical dose calculation point of view, a compromise
has to be found to solve the following problem: most preclinical
studies could use small ﬁeld sizes with a tight ctc spacing and high
peak entrance dose values to achieve a superior tumor control
probability (TCP), while the use of larger ﬁeld sizes and tumor lo-
cations at greater depth using relatively low energy photons would
oblige us to reduce the peak entrance dose values in ranges where
a) the crucial contribution of the valley dose at the tumor is mini-
mized and b) the differential effect on the tumor vasculature from
the peak doses for several hundreds of Gy is reduced as well [29].
One possible option to overcome this problem may be to inter-
spearse these microbeams from multiple ports, where larger ctc
spacing for the normal tissue assures a sufﬁciently low valley dose
and the tighter ctc spacing an optimized TCP [30] in the overlap
region.
A comprehensive MC study comparing different ﬁeld sizes,
target sizes and geometries was performed by Anderson [31]. In
this study a new deﬁnition in addition to the PVDRwas introduced:
PMVDR, the ratio between the mean doses in the peak region and
in the valley region, which may be of interest when absolute valley
dose values shall be respected in comparison to broad beam irra-
diations and may perhaps better represent the dose-volume rela-
tionship that MRT relies on.
Experimental dosimetry
The ESRF is perhaps the most suitable source for future clinical
trials of brain tumors where the spreading of the microbeams due
to cardiosynchronous movement of the tissues must be avoided by
extremely rapid dose delivery. The only other place with concrete
plans for clinical trials in MRT are at the Imaging and Medical
beamline (IMBL) at the Australian Synchrotron in Melbourne. The
very high dose rate at the ESRF represents a challenge in measuring
the dose under broad beam conﬁguration with an ionization
chamber based on the recommendations in the International
Atomic Energy Agency's TRS398 protocol [32]. The current protocol
Figure 2. Dose rate measurements (normalised by the Storage Ring SR current (Gy/
mA/s)) obtained for different currents in order to determine the ion recombination
correction factor.
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dations, performs measurements in a PTW water tank at 2 cm
depth for a 2 cm  2 cm ﬁeld size using a PTW pinpoint ionization
chamber with a volume of 0.015 cm3 (see parameters below)
Table 1.
A standard cylindrical ion chamber cannot be used for syn-
chrotron measurements owing to excessive ion recombination
corrections, corresponding to more than 30% at such dose rates.
Additionally, the source dimensions with a ﬁxed, vertical beam
height of usually 520 micron obliges us to scan the target as well as
any dosimeter to be irradiated through the beam at a typical speed
of 20 mm/s. The standard irradiation procedures for preclinical and
clinical irradiations uses a GUI (Graphical User Interface) that
automatically calculates (see Equation (1)) the correct speed for the
microbeam irradiation as a function of the desired peak entrance
dose to be delivered, the measured dose rate, the current in the
machine, the slit size used and the selected micorbeam size, where
output factors are tabulated from a Monte Carlo calculated library
and scaled to the broad beam ﬁeld conditions.
vzðmm=secÞ ¼ _DðGy=s=mAÞ$IðmAÞ$OFðoutput factorÞ$
zbeamheightðmmÞ
DðGyÞ
(1)
vzðmm=secÞ: scanning speed.
_DðGy=s=mAÞ: measured dose rate
IðmAÞ: machine current (storage ring)
OF: output factor scaling the peak entrance dose to the broad
beam dose at 2 cm depth for a 2 cm  2 cm ﬁeld size
zbeamheightðmmÞ:slit size used to deﬁne beam height.
DðGyÞ: desired peak entrance dose at 3mmdepth to be delivered.
The ion recombination correction using the two-voltagemethod
assumes a constant full illumination of the detector, rendering this
method unsuitable for our purpose. At the ESRF, we have devised a
so-called ramping method reducing the current in the electron
storage ring, which represents the only reliable way to reduce the
dose rate at identical spectral conditions. This current ramping
method allows us to determine the ion recombination correction
resulting in values between 3.7% and 4.7% for an electron current in
the synchrotron storage ring (SSR) ranging from 160 to 200 mA.
Similar results were found by independent measurements using
Alanine dosimeters: 2.35% ion recombination correction at
160.7 mA and 5.5% ion recombination correction at 197 mA (see
Fig. 2). The uncertainty in the absolute dose measurements using
this methodology still exceeds the recommended 3% for RT appli-
cations in humans. We foresee additional measurements using
calorimetry to determine the dose rate at the ESRF to compare with
our ion chambers.
The production of very regular microbeams is a crucial aspect
for MRT to correctly predict the dose from CT data input assuming
perfectly parallel beams all with an FWHM equal to 50 micron.
After several variable MSCs (Archer collimator [17]), Tecomet MSC
[33] the advanced ESRF MSC (EMSC) produced from a solid tung-
sten carbide piece using newwire cutting techniques [34] producesTable 1
Parameters used for the reference dosimetry protocol.
Parameters of interest for reference dosimetry
Phantom material
Ionisation chamber type
Measurement depth zref
Reference point of chamber
Field size
Scan speedperfectly regular beams of 50micronwith a deviation of ±1micron.
This was an important step to be able to assume identical sizes in
FWHM of these microbeams as input data into the MC calculations
for realistic dose computation.
The relativeedose proﬁles at depth can be determined using
several types of detectors, all with their individual advantages and
disadvantages [34]. The most promising results so far were ob-
tained using Gafchromic ﬁlms either in combination with a
microdensitometer [35] or a modiﬁed Zeiss Axio Vert.A1
microscope.
Other potential high resolution dosimeters which are ideal
candidates for the MRT dosimetry include ﬂuorescence nuclear
track detectors (FNTDs) from Landauer (Al2O3 detectors) demon-
strating an excellent resolution [36,37], and a two-dimensional
thermoluminescence (TL) dosimetry system consisting of LiF:Mg,-
Cu,P (MCP-N)-based TL foils and a TLD reader equipped with a CCD
camera and the large size planchete heater developed at the
Institute of Nuclear Physics in Poland [38]. A large body of research
and development over the last 15 years has gone into the devel-
opment of Silicon-strip detectors [39e42] with the potential to
develop an online monitoring system to simultaneously monitor
the peak and valley dose during patient treatment. Such technical
solutions are currently under further development in the frame of a
collaboration grant with SINTEF and the Univ. of Wollongong (see
section III e).
Further examples of new approaches to develop dosimetry
systems to read high doses with high resolution include the use of
samarium doped glasses from research groups in collaboration
with the Canadian Synchrotron Radiation Facility [43e45].
For the ﬁrst time the radiation induced optical absorption in
ﬁve commercially available UV optical ﬁbers under synchrotronValues/characteristics
Water
Cylindrical
2 g cm2
Central axis, at the centre of the cavity volume
2 cm  2 cm
20 mm/s
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“Innovative Methods in Radiotherapy and Radiosurgery using
Synchrotron Radiation (SYRA3)”, in order to evaluate the color
center generation/recovery for use in radiation dosimetry. The ir-
radiations were done at the ESRF synchrotron accelerator, in Gre-
noble, while the tests were carried out at the National Institute for
Laser, Plasma and Radiation Physics, in Bucharest, Romania. The
dose rates were 70.69 Gy/sec/mA and 65.49 Gy/sec/mA since the
samples were exposed in two separate experiments. The total doses
were varied between 5 Gy and 2000 Gy. Under these conditions,
three of the optical ﬁbers proved to be radiation hardened, while
two of them were sensitive to synchrotron radiation exposure. All
the optical ﬁbers showed a recovery of the optical absorption after
storage for 10 days at room temperature [46].
A special setup was developed to monitor the dynamics of the
color centers in the UV spectral range (Fig. 3). The samples sensitive
to irradiation showed a linear dependence of the optical absorption
at l¼ 229 nm, l¼ 248 nm, and l¼ 265 nm, for total doses between
60 Gy and 2000 Gy, after the second exposure to synchrotron ra-
diation. For both samples, the optical absorption remained almost
unchanged at l ¼ 330 nm with increasing dose. By selecting in an
appropriate manner the type of the optical ﬁber to be subjected to
radiation and the dose rate, optical ﬁber based dosimeters can be
developed for on-line dosimetry. As a novelty, the investigations
included some THz spectral measurements of the irradiated sam-
ples, tests which highlighted the irradiation induced changes in the
reﬂectivity of optical ﬁber samples.
Three selected detector systems are presented more in detail in
this paper and plans within the current COST action SYRA3 include
a study to compare the most promising MRT detector systems as
well as advances in broad beam measurements. Sections III c, III d,
and III e will give examples of recent developments and results in
the ﬁeld of high resolution dosimetry.
Radiochromic ﬁlm dosimetry
Introduction: Radiochromic (RC) ﬁlms are self-developing
coloration detectors consisting of a radiation sensitive single or
double layer of diacetylene microcrystals on a thin organic base.
The diacetylene monomers join up upon irradiation, creating long
polymeric chains responsible for the strong optical absorption
[47,48]. The colorless active monomers display main absorption
peaks at about 617 nm and 670 nm at room temperature) and its
lithium salt (LiPCD) in EBT ﬁlms (main absorption peak at ~583 nm
and 635 nm). Various matters concerning radiochromic ﬁlm
dosimetry have already been reviewed in depth, notably publishedFigure 3. The setup used to monitor the dynamics of the color centers in UV optical ﬁbers
optical ﬁber multiplexer; 4 - optical ﬁber mini spectrometer; 5 e optical ﬁber sample; 6 eby the American Association of Physicists in Medicine [49e51].
However, taking into account the recent advances in the ﬁeld, other
topics of prime importance for the use of radiochromic ﬁlms for
therapeutic applications at synchrotron facilities still need to be
investigated.
Spatial resolution and ﬁlm readers: Dose assessment is
traditionally based on linear absorbance measurements using often
“white” light sources, such as those used in ﬂat-bed colorscanners.
The transmission (or reﬂection) image is analyzed for dose
assessment in three wide color channels (RGB analysis) and the
data obtained in either one of them (usually in the red one) or in all
channels [52e54]. Alternatively, spot spectrophotometers, densi-
tometers, and microdensitometers with light sources of appre-
ciable spectral content in the region of intense light absorption are
often used. Low power lasers, such as He/Ne (632.8 nm) and diode
(e.g. 650e670 nm) lasers and broadband red-light emitting LED
sources coupled with band-pass ﬁlters are often used along with
either a photodiode or a photomultiplier.
Flat-bed scanners equipped with “white” light sources and ar-
rays of charged coupled devices (CCD) are useful in the study of
synchrotron radiation ﬁelds for various applications such as
alignment procedures, uniform ﬁlm irradiations and dose-
mapping. However, the currently available commercial ﬂat-bed
scanners have a charge-coupled device (CCD) with the required
resolution, however the Modulation Transfer Function (MTF) of the
system is not adequate to provide spatial resolution for dose proﬁle
measurements in MRT. In that case either spot micro-
densitometers or systems coupled with an optical microscope can
be used.
Environmental effects: Molecular motions inﬂuence the
structure of the polymer. Therefore, the shape of the absorption
spectrum is inﬂuenced by the temperatures during ﬁlm irradiation,
storage and reading, usually shifting towards lower wavelength
with increasing reading temperature.
Humidity and UV exposure (even by sunlight or light from
ﬂuorescent lamps) may also inﬂuence the ﬁlm response by a degree
which depends on the coating used among other things. Radio-
chromic ﬁlms undergo post-exposure signal intensiﬁcation, with
the polymerization-rate decreasing with time. Adequate time has
to elapse between irradiation and measurement to achieve accu-
rate measurements. Thus sticking to a ﬁxed carefully designed
protocol is crucial to obtain reproducible and accurate dosimetric
results with Radiochromic ﬁlms.
Energy response: Taking into account that a) most of the
imparted energy during the therapeutic uses of synchrotron radi-
ation is related to photons of energy less than about 150 keV, and b)subjected to synchrotron radiation: 1 e light source; 2 e optical ﬁber attenuator; 3 e
laptop.
E. Br€auer-Krisch et al. / Physica Medica 31 (2015) 568e583 573the photon spectrumvaries with depth as well as between the peak
and the valley region [55], some corrections may be necessary to
cope with the energy dependence. To partially overcome the en-
ergy response of the ﬁlms, calibration ﬁlms are irradiated under
identical conditions to those previously described in the dosimetry
protocol, referring to absolute dose measurements.
Measurements carried out by Bartzsch [56] indicated a 50%
decrease in the response of HD-810 ﬁlms in water with decreasing
photon energy from 100 keV to 40 keV and an about 15% increase in
the response of HDV2 ﬁlms in the same energy region. Similarly,
simulations by Hermida-Lopez et al. [57] indicated that the EBT and
EBT2 ﬁlms exhibit an energy-dependent response in water in the
energy region from 10 to 100 keV, with a 10% and 40% maximum
reduction at 40 keV, respectively. They predicted that the EBT3
ﬁlms would have a constant response within 2.3% over the entire
energy region. However, in practice, one cannot exclude the po-
tential existence of intrinsic energy-dependence, a factor usually
not taken into account when using radiation transport codes. Thus,
the radiochromic ﬁlm energy-response has to be assessed
experimentally.
Muench et al. [58] showed that the response HD810 ﬁlms to 60
kVp X-rays (28 keVeff) is lower by about 30% than that to 4 MV X-
rays. Kron et al. [59] reported that MD-55 ﬁlms underestimated the
dose by a factor of two when irradiated with a monoenergetic
26 keV synchrotron-generated X-ray beam. Nariyama et al. [60]
studying the energy response of MD-55 and HD-810 ﬁlms re-
ported measurable dose up to 50 and 400 kGy, respectively, and an
under-response relative to 60Co gamma rays to low energy pho-
tons. In HD-810 ﬁlms an almost constant under-response by 20%
was observed in the energy region 30e100 keV, relative to Co-60
gamma rays, and a gradual increase in MD55-2 ﬁlm from about
5% to almost 40% as the energy decreases in this energy region.
Similarly, Cheung et al. [61] studying MD55-2 and HS ﬁlm observed
a gradual decrease of response with decreasing energy from 100 to
30 keV up to about 40% and a large over-response (up to a factor of
ﬁve at 50 kVeff) in XR-T RC ﬁlms.
Oves et al. [62] observed in LiPCD-loaded EBT ﬁlms a 0.76 and
0.81 response to 75 and 125 kVp X-rays relative to 6 M X-rays.
Brown et al. [63] reported responses of EBT, EBT2 and EBT3 ﬁlms to
35 keV synchrotron-produced monochromatic beams of 0.76, 1.24
and 0.98 relative to 4 MV X-rays, respectively. Similarly, comparing
the output factors of X-ray machines in the energy range from 50 to
125 kVp measured by EBT3 and a parallel plate ionization chamber
Gill and Hill [64] reported differences up to only 3.3% in 2.0 cm
ﬁelds. The differences were consistent with the estimated total
uncertainty. On the other hand, Villarreal-Barajas et al. [65] irra-
diating EBT3 ﬁlms with 70e300 kVp X-ray beams reported a
gradual reduction of the response with decreasing energy from
0.94 at 168 keVeff down to 0.79 at 32 keVeff using the red channel
of RGB images and even lower using the blue one (0.83 and 0.74,
respectively). Moreover, Massillon et al. [66] found a dose-
dependent reduction in the response of EBT3 ﬁlms to 50 kVp X-
rays (20 keVeff) up to 11% relative to 6 MV X-rays. In conclusion,
even for ﬁlms such as EBT3 that are often referred as dosimeters
with no energy-dependence, extra care has to be taken when
synchrotron beams are used for therapeutic purposes.
Microbeam ﬁelds: A signiﬁcant number of investigators have
exposed ﬁlms in MRT to study among other things, relative output
factors, transversal dose-proﬁles and depth-dose distributions. The
measured valley doses in such proﬁles have in general been 10%e
15% higher than those predicted by MC simulations.
At the Spring-8 synchrotron in Hyogo, Japan, Crosbie et al. [35]
irradiated two types of radiochromic ﬁlms that differed substan-
tially in their dose response (HD-810 and EBT), using an array of
25 mm/200 mmmicrobeams (mean energy 120 keV). Using a Joyce-Loebl micro-densitometer as a ﬁlm-reader, they found that the
PVDR in a solid-water phantom reached its maximum value at the
depth of 1 mm, decreased with depth up to 10 mm and remained
practically constant at larger depths.
Martinez-Rovira et al. [24] irradiated HD-810 ﬁlms with 50 mm/
400 mm micro-beams at the ESRF with a photon spectrum ranging
from 27 to 600 keV (mean energy 100 keV) and read them using a
microdensitometer similar to the one used by Crosbie et al. The
comparison of the PVDR values measured at various depths
following irradiation with ﬁelds of various sizes with those pre-
dicted by simulations generally resulted in a lower measured PVDR
value, reﬂecting approximately a 10% higher valley dose.
Finally, Bartzsch [56] also irradiated HD810 and HDV2 ﬁlmswith
MRT beams also at the ESRF and read them using an inverted op-
tical microscope coupled with a CCD-camerawith a nominal spatial
resolution of 5 mm. Films were also irradiated homogeneously at
2.0 cm depth in a solid-water phantom for calibration purposes.
The doses given to these ﬁlms were assessed by ionization chamber
measurements employing the IAEA TRS398 protocol with marginal
modiﬁcations. Film dosimetry indicated that the peak and valley
doses up to 6 cm depth in the phantom were similar to those
predicted by simulations within the measurement uncertainty.
However, comparing the signal of the two ﬁlm types, it was found
that the peak dose values of the HDV2 ﬁlms were slightly higher
than those of the HD810 ﬁlm, with an opposite situation in the case
of the valley dose, resulting higher PVDR values when the HDV2
ﬁlms were used. Such differences were attributed by the author to
potential differences in the energy response. The investigator also
observed, as anticipated, higher valley doses at the centre of the
radiation ﬁeld than close to its edges, resulting in smaller PVDR
values in the central region of the ﬁeld. Finally, in an attempt to
simulate a two-ﬁeld MRT treatment, dose measurements were
carried out in an anthropomorphic head-phantom at distances of at
least 1 cm from the skull. The deviations between the measured
peak and valley doses at four studied depths and the predicted ones
by simulations were below 5% in the peak region and between 10%
and 15% in the valley region.
Potential applications of PRESAGE® dosimeters and optical CT
MRT represents a challenging dosimetry problem that requires
measurements with both high spatial resolution and high dynamic
range. Satisfying results have been achieved with the various
dosimetry systems described in the other sections of this article
and each approach has its individual advantages and disadvan-
tages. However, for the eventual adoption of MRT in the clinic, we
must add to our list of requirements the ability to make measure-
ments over a large ﬁeld-of-view (FOV) and in three dimensions.
High spatial resolution often comes at the price of limiting both the
region of space sampled and the dimensionality of the information
obtained. For example, single detectors have limited sensitive areas
and must be translated through the region-of-interest, involving a
series of separate irradiations, rather than necessarily mimicking a
single patient treatment. While having precise peak and valley
measurements is very important, there is also an increasing need
for 3-D measurements of dose as MRT irradiation geometries
become more complex. A further important consideration is the
need for comprehensive end-to-end veriﬁcation of the entire MRT
treatment chain. A dosimeter is needed that can follow the entire
“patient journey”, with multiple repositioning steps, from the
initial X-ray CT scan, through planning with the newly developed
TPS (as discussed in Section Medical Physics aspects in SSRT) to the
ﬁnal treatment. This would provide quality assurance not just for
the apparatus and the physics involved, but also the software,
workﬂow and operator. 2-D ﬁlm dosimetry satisﬁes some of these
Figure 5. Still picture from real-time video taken on ESRF beamline ID-17, showing a
sample of PRESAGE® changing colour in response to an MRT X-ray beam. Full video is
available as a supplementary resource (https://www.dropbox.com/s/yxwin7sd6fmxetr/
Fig_PR2_movie.avi?dl¼0, https://www.dropbox.com/s/d7kg8yxqb4nme85/Fig_PR4a_
movie.mov?dl¼0 and https://www.dropbox.com/s/aruuyayzhsyig2v/Fig_PR4b_movie.
mp4?dl¼0).
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tricky, time-consuming and involves multiple readout steps if ﬁlms
are stacked in 3-D.
For all of these reasons, methods of 3-D dosimetry comple-
mentary to the other approaches described in this article have been
under active development over recent years. In the ﬁeld historically
known as gel dosimetry, two readout modalities have emerged
more generally as leading candidates for quantitative dose imaging:
Magnetic Resonance Imaging (MRI) of both radiochromic Fricke
gels [67,68], and polymer gels [69]; and optical computed tomog-
raphy (CT) [70,71]. Whilst the MRI-based techniques have been
used successfully for dosimetry of SSRT protocols at the ESRF [72],
they have proved unsuccessful for MRT, both because the gels
themselves are not sufﬁciently robust to very high dose rates and
because the available spatial resolution is not high enough to
characterise microbeams of order 50 mm [73,74]. During the
remainder of this section, we will focus on recent developments in
the alternative method of 3-D optical CT microscopy using the
radiochromic plastic polymer known as PRESAGE®.
Materials and methods
PRESAGE® is a solid plastic chemical dosimeter based on clear
polyurethane mixed with a leucomalachite green reporter dye and
a number of organic and/or metallic initiators [75]. A radiochromic
reaction is induced after exposure to ionising radiation, resulting in
a local change in optical density of the plastic. Effectively, the
PRESAGE® acts as a “3D radiochromic ﬁlm” and the response to
radiation is highly linear with dose at the normally imaged wave-
length of 633 nm, compatible with both HeNe laser and light-
emitting diode (LED) light sources (see Fig. 4a and 4b).
Whilst details of the time-dependence of the dose response of
PRESAGE® are currently the subject of active research [76,77], the
response is sufﬁciently rapid for the dosimeter to have a place in an
online dosimetry system for benchmarking the MRT system and
even prior to patient irradiation as evidenced by the video clip
associated with Fig. 5 (supplementary multimedia resource).
Advantages of PRESAGE® include excellent spatial resolution,
high dynamic range [78], dose-rate independence and the ability to
record the dose distribution in three dimensions, givingmuchmore
ﬂexible and realistic dosimetry. To date the highest resolution
measurements have been made via ﬂuorescent microscopy with
pixel sizes down to 78 nm [79]. The corresponding disadvantages
relate primarily to the fact that PRESAGE® is a chemical dosimeter
with a relatively complex composition. A number of the constitu-
ents, particularly the polyurethane base, are supplier-dependent,
with batches whose properties do not remain constant over time.Figure 4. a and b Cuvettes of PRESAGE™ irradiated with a range of doses and the opThe manufacturer has also investigated a number of different for-
mulations over the course of the research programme described
here and the samples received have displayed differing sensitivities
to radiation and ambient temperature, with variable degrees of
time-evolution of their optical density post-irradiation. The inter-
and intra-batch variability still needs to be investigated until the
optimum formulation is found and characterized. Thus, whilst
relative dosimetry is reliable [80], moving forwards from current
results to absolute dosimetry will be challenging.
Development of themicro-imaging scanner has involved several
upgrades during the programme to date. After an initial feasibility
study [81], the system reported in Ref. [80] was able to reconstruct
images of 5123 voxels from raw datasets consisting, typically, of
around 1000 projections, each of 512  512 pixels, acquired in 1 h
10 min. For the current system, this has been reduced to less than
3 min with the addition of a new camera (Zyla sCMOS, Andor
Technology PLC, Belfast, UK) with a large pixel array and fast frame-
rate. Reconstruction speed has been improved by the addition of an
acquisition PC with 256 GB RAM, with the option of GPU acceler-
ation. This time-frame for scanning makes it much more feasible to
use optical CT as a beamline veriﬁcation system for irradiations
before treatment. The small size of the scanner and relatively low
cost of the parts means it is possible to locate one inside the control
hutch of the beamline. Other additions to the system are motorisedtical absorbance of the cuvettes as measured at 633 nm by a spectrophotometer.
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reproducible positioning of individual samples. This potentially
means absolute changes in optical density can be measured by
registration of pre- and post-irradiation optical CT scans.
3-D visualisation studies
Irradiation of PRESAGE® samples took place over two visits to
the ID17 biomedical beamline at the ESRF and a general description
of the irradiation conditions and protocols is given in Ref. [80]. The
3-D dosimetry programme has considered complex irradiations
such as multi-port cross-ﬁring [30], interlacing [82] and different
collimation options, which are difﬁcult to verify with planar do-
simeters. Cylinders of PRESAGE® with diameters of 22 mm and
9.7 mm, supplied by Heuris Pharma (Skillman, NJ) were irradiated
using a variety of MRT geometries. Figs. 6e8 show an example in
which one of the 22mm PRESAGE® cylinders was mounted inside a
radiosurgery head phantom (Model 605, Computerized Imaging
Reference Systems, Incorporated (CIRS), Norfolk, Virginia, USA). AFigure 6. Example of PRESAGE® in use at the ESRF inside an anthropomorphic head
phantom. The custom holder is divided into multiple plates, between which elements
of a radiochromic ﬁlm stack can be inserted, thus allowing independent measurements
in 3-D for correlation between methods. Using the head phantom, it is possible to test
the entire treatment process as described in the main text.
Figure 7. Still pictures from movies of reconstructed optical CT data from the PRESAGE® s
number of complementary ways of visualising the 3-D data. Note the presence of high-inten
the PRESAGE® samples and exemplify one aspect of the ongoing research required to create
hand panel demonstrate issues with the back-projection reconstruction, which also need ad
com/s/yxwin7sd6fmxetr/Fig_PR2_movie.avi?dl¼0, https://www.dropbox.com/s/d7kg8yxqb4
Fig_PR4b_movie.mp4?dl¼0).cross-ﬁring MRT treatment with three ports separated by 60 an-
gles was applied to the head phantom, with careful alignment of
the phantom by eye such that the beams would cross in the centre
of the PRESAGE® sample. The procedure simulated an attempt to
hit a deep-seated tumor.
Data were acquired using the recently upgraded optical CT mi-
croscope. 1000 projection images of matrix size 512  512 pixels
were reconstructed as a 5123 voxel volumewith isotropic voxel size
20.8 mm. Fig. 6 shows the dosimeter in situ inside the head phan-
tom, while Figs. 7 and 8 present the acquired 3-D data in a variety of
formats. Each is useful for visualising different aspects of the dose
distribution. The movies associated with Fig. 7 (available as online
supplementary resources) provide a graphic illustration of the
quantity of data acquired and the wide ﬁeld of view covered, and
they make it possible to visualise in 3-D the planar nature of the
individual microbeams. By contrast, the multiplanar reformatting
(MPR) of the data in Fig. 8 illustrates precisely why access to the full
3-D data is so vital. The top row of images in Fig. 8 shows single
planes through the dataset in, respectively, sagittal, axial and cor-
onal orientations, which mimic the results one might expect to see
from 2-D ﬁlms positioned within the phantom in these orienta-
tions. Although the coronal image is easy to interpret in terms of
the applied multiport irradiation, the sagittal and transverse im-
ages aremore confusing.With a realignment of the imaging axes by
just a few degreesd an operation that is simple but that needs to
be very precise andwould be virtually impossible with physical 2-D
ﬁlms, given the extremely narrow beams d the interpretation
becomes straightforward. Considering the bottom left image
(“sagittal-oblique”), we see that there are three grey levels: the
lowest level corresponds to a single microplanar beam and is
visualised as a solid rectangle from end to end of the sample and
occupying the entire diameter. The mid grey corresponds to a set of
lines on which exactly two microplanar beams cross, whilst the
bright lines in the middle are the loci of points where all three
microplanar beams cross, leading to three times the radiation dose.
The bright white “ﬂecks” in Fig. 7 correspond to microscopic
imperfections in the PRESAGE® samples. These lead to high ab-
sorption and there is a need for ongoing research to create
improved samples. Similarly, the black streaks below the dose
distribution in the left hand panel illustrate image artefacts arising
from the back-projection reconstruction, which also need
addressing.ample loaded into the CIRS head phantom. Together with Fig. 8, these demonstrate a
sity image artefacts in both images. These correspond to microscopic imperfections in
improved samples. Similarly, the black streaks below the dose distribution in the left
dressing. Full videos are available as a supplementary resource (https://www.dropbox.
nme85/Fig_PR4a_movie.mov?dl¼0 and https://www.dropbox.com/s/aruuyayzhsyig2v/
Figure 8. Multi-planar reformatting (MPR) presentation of the optical CT data for the PRESAGE® sample of Figs. 6 and 7. Top row: sagittal, coronal and axial data as they are
visualised directly from the optical CT scanner (note that current experimental arrangement does not link the rotation of the axial slice to the true physical azimuthal angle of the
sample during irradiation). Bottom row: same dataset after minor axis tilts.
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quality and it is straightforward to verify whether radiation has
been delivered to the required location in sample. Notice that the
two angled beams are asymmetrically distributed in the images,
such that the region irradiated by all three beams is triangular
instead of hexagonal as intended. This represents an offset of
approximately 2 mm in the crossing point of the beams. Such
deviations from plan are extremely hard to deduce during the
course of the experiment from ﬁlms placed on the proximal and
distal surfaces of the phantom during irradiation and this study
emphasises the difﬁculties of performing such treatments on non-
superﬁcial tissues.
One valid and immediately available function of optical CT is
therefore simply to act as a non-quantitative adjunct to other more
accurate forms of dosimetry. In this mode, optical CT is already
more than capable of simple “hit or miss” assessments, as well as
quality assurance of other aspects of the delivery, such as the
microbeam width and spacing, together with appropriate syn-
chronisation of the shutter opening and goniometer motion.
At the time of writing, an automated patient positioning system
has been developed, but is not yet implemented in the MRT
Graphical User Interface (GUI) at the ESRF [83]. However, a treat-
ment planning system is now in place and a clear goal for the future
use of PRESAGE® is in contributing to the commissioning of any
fully integrated planning and positioning system for conformal
image-guided MRT from several ports, as described in Section
Theoretical dose calculations in microbeam radiation therapy and
section Towards conformal image guided MRT.
Quantiﬁcation and resolution issues
The role outlined above, while important, is unnecessarily
limited. As has been shown previously [84], optical CT is also a fullyquantitativemodality, with a linear response over a dose range of at
least 10e80 Gy. Two issues remain to be resolved before optical CT
can be used to verify quantitatively 3-D MRT treatment plans: (i)
limited spatial resolution; and (ii) the methodology for aligning
imaging and simulation data.
The resolution problem has been previously investigated [84]
where it was found that the apparent doseeresponse of the opti-
cal CT system can vary with width of irradiated “slit” patterns. The
measured peak dose is lower than expected and the valley doses
correspondingly over-estimated due to blurring effects as the slit
width decreases. This is a straightforward manifestation of the
modulation transfer function of the imaging system d which can
be measured in a variety of ways [80] d illustrating the fact that
signiﬁcant changes in pixel value occur even for structures that are
several times the nominal spatial resolution. Whilst this type of
effect is commonly tolerated in qualitative diagnostic imaging,
resulting as it does in a reduction in image contrast, it leads to
serious problems in the quantitative imaging of microbeam radia-
tion dose.
Although themicrobeams are easily visualised, early attempts to
measure the PVDR gave signiﬁcantly lower results than expected
fromMonte Carlo andﬁlmmeasurements for the reasons illustrated
above. A beam proﬁle measured using our original microscopy
system is seen in Fig. 9a. The microbeams were nominally 50 mm in
width,with a center-to-center (ctc) distance of 400 mmandﬁeld size
(3 3) cm2 deposited in a 9.7 mm diameter PRESAGE® sample. The
ctc distancewasmeasured byoptical CT to be (390± 20) mm, in good
agreement with the expected value. However, the PVDR estimated
fromthis dataset at a depth of 143mmwas 4.2with a range [3.3, 6.1].
By contrast, for a broadly similar depth of 100 mm in a (3  3) cm2
ﬁeld, the measured PVDRs were 15 ± 3 (Monte Carlo) and 13 ± 2
(ﬁlm) [24]. For various technical reasons, the optical CT scans
measured at that timehadanuncertain baseline, as indicated,which
Figure 9. a and b Dose proﬁles across microbeams measured with original and improved systems (left and right respectively). To reduce noise, proﬁles were averaged in the two
orthogonal directions to the microbeam variation resulting in effective pixel size of 110 mm/104 mm in those directions and pixel sizes of 20.7 mm/5.2 mm across the proﬁles (left/right
respectively). The improved proﬁle is from a similar irradiation but with more frequent sampling showing a sharper proﬁle shape. The baseline measurements come from average
unirradiated regions on other samples, hence the uncertainty.
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the consequent uncertainties in the valley dose. This can be resolved
in the future if a system is available at the ESRF so an accurate pre-
scan of the sample before irradiation can be acquired. The more
serious issue is that the mean value is only 30% of what is expected,
because of the effects of the limited spatial resolution. From a basic
simulation of our system we have found that for beams of width
50 mm, a spatial resolution of 10 mmor better is required to measure
the true peak value after ﬁltered backprojection reconstruction.
Given the fact that having a measurement of how the PVDR
varies with depth would be very helpful, we have tried to improve
the system to achieve better resolution and obtain more accurate
peak and valley measurements. The experiment of Fig. 9b makes
use of the full matrix size of the new camera (2048x2048 pixels,
3200 projections) and an optimal magniﬁcation, resulting in a
reconstructed voxel size of (5.2 mm)3. As the matrix size of the in-
dividual projections increases, more projections are required to
satisfy the Nyquist sampling criterion, leading to an increase in
scanning time to 30 min for this case. For lower noise data, ﬁve
projections were averaged for each angle resulting in a ﬁnal scan
time of 1 h. Proﬁles were measured at 40 mm depth (see Fig. 9b)
giving a PVDR of 6.4 ± 1.5 (expected values 17 ± 2 Monte Carlo,
13 ± 3 ﬁlm [24]). Although this new measurement seemingly
represents only a small improvement and the true value of the
PVDR is still an underestimate by more than a factor of 2, the valley
is noticeably ﬂatter in the new results and the density of mea-
surement points is now sufﬁciently high to capture the true peak,
once the blurring effects introduced by the optical imaging chain
have been removed. At the moment, the peak measured is still
lower than expected due to the limited MTF of the optical system.
The next step in the research is to make more accurate measure-
ments of the imaging point-spread function and use these to
deconvolve the raw data. Early indications (data not shown) sug-
gest that by so doing, we will recover a value that more closely
matches the data available from other techniques.
As alluded to earlier, the other unsolved question for PRESAGE®
dosimetry is how to compare the results of 3-D imaging of this type
with a 3-D MRT treatment plan. Clearly, the exceedingly small
diameter of the microbeams means that alignment of datasets will
be a hugely challenging problem. It remains to be determined what
the appropriate quality assurance measures will be that correspond
to the ubiquitous gamma analysis in routine external-beam radio-
therapy [85]. Despite the improved resolution, absolute dosemeasurements of the peak dose are not yet feasible with our
PRESAGE® dosimetry system, but the determination of the valley
dose remains the most important parameter, since it represents the
threshold dose for the normal tissue tolerance. For such important
benchmarking experiments, the PRESAGE® dosimetry system is
currently the best choice for ultimate conﬁrmation of a 3-D valley
dose distribution prior approval of a treatment plan.Si-based multiple strip detector systems
In order to meet the safety standards in treatment planning and
quality assurance for preclinical MRT trials, an emergency beam
shutter must be in place in case of any beam anomalies. The pri-
mary role of the beam monitor is to be one of several active and
passive emergency interruption mechanisms designed to respond
instantaneously upon detection of any abnormality in the MRT
beam delivery. The beam monitor is coupled directly to readout
electronics with a rapid time response, so as to be a real time on-
line monitoring system. Silicon radiation detectors, manufactured
in well-established technologies have been widely used in X-ray
detection for over 20 years. Current available technology allows
the feasibility of direct coupling of silicon sensors to their associ-
ated readout electronics with extremely high spatial resolution;
thus providing an attractive solution as an active beammonitor for
MRT.Multiple-strip detector for MRT
The PVDR is a very important quantity to be monitored during
an MRT treatment. Within the framework of the 3DMiMic project
[86], a novel silicon sensor with multiple strips (or channels) has
been proposed to monitor the X-ray beams that make up an entire
microbeam array in MRT. Due to the extremely high dose rate in
MRT, one key issue when using conventional silicon sensors is the
large amount of charge generated by the X-ray photons. Upon
exposure to an array of microbeams, the unusually high level of
generated charge in a conventional silicon sensor will saturate the
entire readout system. Moreover, the generated charges then
diffuse in all directions, resulting in an inability to distinguish both
the position and the intensity of the X-ray microbeam. Silicon
sensors with various detailed conﬁgurations have been designed to
address these issues by taking four key strategies.
Figure 11. A sensor mounted on a printed circuit board compatible with a 256-channel
readout system.
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reduce the available ionization volume. Any beam pertur-
bation as well as the heat load on the silicon sensor is ex-
pected to be minimized using this approach.
b) Isolation structures such as ‘guard-ring’ and ‘p-stop’ (a
heavily doped region that provides high recombination
probability of the generated charge) were designed to sur-
round each individual strip to limit the amount of charge
reaching the readout electronics, as shown in Fig. 10. In
addition, the guard isolation reduces the charge sharing be-
tween adjacent strips for better identiﬁcation of an X-ray
peak intensity position measurement.
c) Low resistivity substrates with a high doping concentration
were investigated. The high concentration of dopants in-
creases the recombination rate of the generated charge upon
ionization thus resulting in a lower total collected charge and
generated signal.
d) Particular care was taken in assuring the longest possible
lifetime of the devices. The expected radiation damage to a
silicon detector for the X-ray photon energies involved in the
MRT is mostly related to the charging up of the surface oxide
layers. In order to assure a proper operation of the sensor
after very large radiation doses, speciﬁcally tailored p-spray
and p-stop implantations were used in order to assure inter-
channel isolation and maximise the operating voltage. A
small amount of bulk damage will also be present but this
will not cause any concern due to the very largemagnitude of
the signal generated by the MRT beam. Periodical re-
calibration of the sensor will take into account efﬁciency
losses due to bulk damage without compromising the oper-
ation of the system.
Based on the design strategies listed together above, several
sensor designs were implemented, and a set of silicon wafers with
high doping concentration levels were fabricated at SINTEF MiNi-
Lab. Awet chemical isotropic etch that is well-established in silicon
fabrication technology was used, and is the most critical step so as
to reduce the sensitive volume down to 10 mm thick. Special
attention was paid to the mechanical design of the sensor to
maintain their mechanical stability and the feasibility for general
handling. Prior to the fabrication, the proposed designs were fully
investigated using device simulations, performed on a small region
of the overall strip design as indicated in Fig. 10.Figure 10. Design layout of one implemented strip design, showing the single strip
that monitors the peak intensity that is surrounded by the isolation structures (guard-
rings and p-stop) to address the saturation issues due to the high dose rate in MRT.Sensor, assemblies and test set-up
The fabricated devices were screened by parametric testing such
as current and capacitance measurements. Working devices were
then selected for experimental testing with microbeam arrays at
the biomedical beam-line ID17 at the ESRF. Each sensor was
mounted on a printed circuit board (PCB), compatible with the
chosen 256-channel readout system that has the capability to read
out all the channels on a 128- or 256- channel sensor. The system is
based on a commercially available analogue front end readout chip
(AFE0064 from Texas Instrument), that was designed and conﬁg-
ured by the Centre of Medical Radiation Physics, University of
Wollongong, Australia. One of the wire-bonded detectors mounted
on a PCB is shown in Fig. 11. Detailed studies of the sensors on
device level are currently on-going through comparison with
simulation results.
Six sensors of various designs were mounted and tested at the
ID17 beamline over two periods, September and November 2014.
The performed experiments aimed to identify the most suitable
sensor conﬁgurations for MRT, and to provide a veriﬁcation of the
sensor functionalities and on-line capabilities. Fig. 12 shows the
experimental setup at the beamline where the sensor assembly isFigure 12. Experimental setup at ID17 at the ESRF. The sensor assembly is connected
to the multichannel readout system and inserted in a shielding box mounted on a
motorized stage, placed close to the multi-slit collimator that provides the microbeam
array.
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connected to either a multi-channel readout or a single-channel
electrometer. The entire assembly was then secured onto a
motorized stage with 10 mm precision in the x-, y- and z-directions,
and was placed as close as physically possible to the multi-slit
collimator (MSC) that striates the homogeneous synchrotron
generated X-ray beam into an X-ray microbeam array in order to
minimize the effects of beam divergence. The MSC to sensor dis-
tance was estimated to be between 15 and 20 cm in this experi-
ment, giving a beam divergence of roughly about 1 mm between
adjacent microbeam peaks.
First results from ID17 at the ESRF
Two measurement approaches were used in the experiments
that took place at the ID17:
1. Study of one single channel with respect to an array of micro-
beams by measuring the generated current in a single strip
using an electrometer.
2. Study of the behaviour of a multiple strip sensor with respect to
an array of microbeam using a multiple channel readout system
that provides both the position and beam intensity of the entire
arraySingle channel measurement
In the single channel measurements, the generated current in
one single strip and the isolated guard-ring structure were
measured by two separate electrometers. The device was then
scanned across an array of 25 microbeams, spaced by a nominal
pitch of 400 mm (as deﬁned by the microbeam collimator). The
generated current in the strip was recorded at a time interval that is
sufﬁcient for the device to shift by 10 mm in the x-direction. One
complete scan would therefore consist of 1000 current measure-
ments that correspond to the x-direction of the array at a step of
10 mm; a simple method that can demonstrate the capability of
beam monitoring in a single strip without the complexity of a
multi-channel readout system with the radiation induced current
measurments acting as an independent calibration of the current
measured by the multichannel readout system. Sensors with
different designs such as strip length and different doping con-
centrations were tested using this approach. Fig. 13 shows one of
the obtained measurements for a single strip operated in passiveFigure 13. First results from a single channel measurement by scanning a single strip acr
scanning period (b) The peak intensity recorded around position x ¼ 5.75 mm to illustrate
result of a ﬁt to the response model described in the text. (For interpretation of the referencemode (no bias voltage was applied on the sensor) that has a strip
length of 100 mm and a resistivity of 5 U cm while the wiggler gap
was set to be 40 mm. The current recorded was interpreted as
current counts, an arbitrary unit given by the data format on the
instrument readout system at the ESRF. This ﬁrst measured result
clearly demonstrated that all 25 microbeams were correctly
reconstructed by the single strip despite the scanning step limited
by the motor precision (Fig. 13a); this is further illustrated by a
more detailed plot of a single peak in Fig. 13b. Simulation studies of
the charge collection efﬁciency proﬁle (the response function) have
been performed [86], and the charge collection proﬁle is quite
smeared, but with an FWHM (Full Width at Half Maximum) that is
consistently 6.4 mm.
A simple model of the response can be made by assuming that
the charge collection efﬁciency function is Gaussian around the
strip, and that the microbeam intensity proﬁle is ‘box shaped’
(uniform over 50 mm) with a sharp cut-off at the edges. The ﬁt
result gives a width of the microbeam of 49.5 microns, and a sigma
of the gaussian of 9.3 microns, and is shown in Fig. 13b. The ﬁtted
values are very reasonable, given prior knowledge of the sensor and
the microbeams. The disagreements observed, particularly in the
valley regions are to be expected. The assumed sensor response
function and the intensity proﬁle are very simpliﬁed models.
Further investigations are needed to fully understand the details, in
particular in regionswhere the valleys are approaching the edges of
the microbeams. It is also to be noted that the pitch of the micro-
beams at the detector location is found to be about 401 mm
consistent with the slight divergence of the synchrotron generated
x-ray beam.
Although the recorded current counts demonstrated the ability
of beam proﬁle reconstruction in a single strip, the actual current
values are crucial in choosing the most suitable sensor conﬁgura-
tion in terms of signal saturation in a ﬁnal readout system. The
radiation induced generated current in a single strip current was
therefore recorded manually and was found to vary from a few nA
to 100 nA depending on the wiggler gap that was implemented and
the synchrotron storage ring current. The generated current from
the isolation guard ring structure were also recorded to be a few mA
when the wiggler gap was set to be 24.8 mm.Multiple channel readout
The secondmeasurement approach was performed using a 256-
channel readout system. The readout system integrates the input
(generated current from the sensor), which is then sampled at anoss an array of 25 microbeams. (a) Intensity as a function of position over the entire
a more detailed beam proﬁle recorded by a single channel. The red line describes the
s to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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maximum charge that could be integrated per sample was 9.6 pC.
Given the sampling rate, and charge collected per sample relative to
the full range, the sensor current can be estimated. The key goal of
this measurement is to investigate whether the designed multiple
strip sensors can provide an accurate peak intensity measurement
of an entire microbeam array; the ultimate goal of having a real-
time on-line beam monitor for the MRT treatment. The measure-
ments were performed with an array of 33 microbeams centered in
the middle of the sensor (channel 64) where the sensor was
exposed to the X-ray microbeam array for 2 s. Fig. 14 shows the
mean current per channel recorded at an sampling rate of 1 kHz, for
a wiggler gap of 24.8 mm. In this case, the length of the sensor
strips was 250 mm (microbeam X-ray beam height 520 microns),
and the material resistivity was 5 U cm. The largest charge de-
positions per sampling of peak intensities were at around 17% of full
range, while those in between to microbeams (typically referred to
as the valley) were around 0.5%. These signal levels were clearly
offset from the ‘no beam’ samplings which were around 0.2 ± 0.1%.
Further investigations (gain linearity, zero level offsets, crosstalk
between strips etc.), are necessary before estimating reliable
PVDRs.
The currents appeared to be rather uniform around the center of
the array but gradually decreasing on the left- and right-hand side
edges of the array. The roll-off in the measured peak current is
primarily due to the small mismatch of the microbeam peak pitch
(402 microns) and the silicon strip detector pitch (100 microns) at
the measurement position. This mismatch is caused by the X-ray
beam divergence. The mismatch increases to the point where the
strips at the edges appear to be signiﬁcantly misaligned with the
microbeams. When a microstrip is aligned at the edge of a micro-
beam, only half the intensity will be seen, relative to the intensity
seen in strip well aligned in a microbeam centre. With the detector
and microslit designs at hand, this effect can only be avoided by
placing the sensor as close as possible to the MSC. The latest test
results have shown great improvements when the MSC to sensor
distance is reduced by 10 cme10 cm. This conﬁrms that the ideal
solution will be to mount the sensor inside the MSC box within
close proximity to the multislit collimator.
The collected data obtained for various sensor conﬁgurations as
well as different operating conditions are currently being studied in
details. The analyzed data together with a comprehensive study on
sensor level will be published in a separate article. Further tests are
also in the pipeline in the coming months for both full sensor as-
sembly and simpliﬁed test devices that have only a few channels.Figure 14. Average currents from 2000 samples over 2 s in each channel in a multi-
strip sensor with 250 mm strip length. The uneven proﬁle of responses is explained by
cumulative misalignment between strips and microbeams.Performance characteristics such as charge collection efﬁciency and
post radiation damage performances will be carried out. The
comprehensive test plan will identify the ideal silicon sensor
conﬁguration that can potentially be integrated into the ESRF
control system, speciﬁcally for the MRT treatment.
Towards conformal image guided MRT
An image-guidance protocol has been developed [83] which
allows for precise conformal microbeam irradiations from multiple
ports, a technique that is mandatory for treating deep-seated tu-
mors with MRT at ID17. By knowing precisely the tumor position
inside the patient, the safety margins for the irradiation ﬁeld may
be reduced, thus increasing the PVDR and sparing especially the
healthy tissue at the beam entrance. The same positive effects arise
from the application of conformal radiation ﬁelds, which are
adapted to the tumor outline, in contrast to the rectangular ﬁelds
that have been applied in preclinical research so far.
The presented protocol is an extension of a protocol used at the
Animal Oncology and Imaging Center in Hünenberg, Switzerland,
and is based on the use of lead pellets attached to animal patients
(typically cats and dogs) on prominent anatomical spots and on a
bite block. These markers are in place during CT imaging for
treatment planning and during the treatment session. The treat-
ment planning platform VIRTUOS [87] is used for treatment plan-
ning, where the target volumes and the positions of the lead
markers are identiﬁed and the directions of the treatment beams
are deﬁned.
Prior to irradiation, stereoscopic radiographs are taken of the
patient on the sample stage, where the lead markers serve as clear
reference points. By back-projecting the marker position along the
projection axis of the imaging system for two images from different
points of view, the three-dimensional position of the marker may
be reconstructed at the crossing of both axes.
After conversion of the beam directions, target points, and
marker positions from the treatment plan, where they are stored
in the common LINAC geometry (two rotational degrees of
freedom for the beam, one rotational degree of freedom for the
patient), to the three rotational degrees of freedom of the kappa-
goniometer at ID17, the actual positions of the markers are
compared to the desired position from the TPS. Here, a
quaternion-based algorithm [88] computes the best translation
and rotation, which minimize the squared distance between actual
positions and desired position. After application of this transform
to the sample stage, an additional projection image form beam's
eye view is taken and overlaid with information from the treat-
ment plan (e.g. desired marker position, target point, target vol-
ume), thus offering an easily human-readable veriﬁcation of
proper alignment.
The imaging of the patient is done using the ID17 wiggler-
induced X-ray beam (25 mm wide, 0.2 mm high), which require
scanning the patient vertically through the beamwhile acquiring a
sequence of projection images and repeating the procedure for
several columns. The resulting data is stitched together adequately
to get a projection image whose maximum dimensions are limited
to 13 cm  13 cm by the ranges of the motors involved.
The imaging dose has been measured with two different ioni-
zation chambers, the PTW Semiﬂex 31,010 chamber with 0.125 cm3
sensitive volume and the Radcal 10X6-6 detector with 6 cm3 sen-
sitive volume. Since the X-ray beam does not have a homogeneous
intensity at the wiggler gap used for imaging, the detector reading
has been corrected with a factor generated by numerically inte-
grating the inhomogeneous beam intensity proﬁle over the sensi-
tive detector volume, revealing an effect of approximately 2% on the
Semiﬂex detector and 15% on the Radcal detector. Furthermore,
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were applied. The resulting entrance surface air kerma ranges be-
tween 3.5 mGy and 12 mGy depending on the beam intensity
chosen. In all conﬁgurations the lead markers were clearly visible
on radiographs taken of an anthropomorphic head phantom, but
for low doses ﬁne details were covered by detector noise.
Comparing these ﬁndings to diagnostic reference levels for human
head radiographs [89], which are quoted as 3 mGy for lateral and
5 mGy (entrance surface air kerma) for anterior-posterior skull
imaging, proves the safety of the imaging procedure.
Several tests of the imaging procedure have been performed
with the same anthropomorphic head phantom to benchmark the
precision of two different protocols: A ﬁrst series of irradiations
using four lead markers (~1.7 mm diameter), which were removed
after CT imaging and placed again on the phantom for irradiation,
and a second series using four smaller titanium markers (~1.0 mm
diameter), which were not removed from the phantom. The former
protocol was meant to stay as close as possible to the procedure
that will be applied in upcoming veterinary trials, while the latter
focusing on maximum precision from the technical point of view. A
total of six treatment plans of the ﬁrst protocol and two treatment
plans of the second protocol were applied, while radiochromic ﬁlm
placed at the target point inside the phantom recorded the actual
point that was irradiated. Conformal irradiations were carried out
for the second protocol to show the feasibility of this technique.
The maximum deviation from the targeted point measured for
the ﬁrst protocol was 1.65 mm, while the maximum deviation for
the second protocol was of 0.57 mm. Additionally the angular
misalignment was measured for the ﬁrst protocol, which gave a
maximum deviation of 1.47. The alignment of the conformal mask
has shown to be accurate. The installation of a synchronized slave
motor for the separate movement of the conformal mask is fore-
seen to prevent vibrations of the mask during the movement,
which has been revealed by these experiments that used a lever
arm for synchronization.
With the development of image-guided conformal MRT, the
ESRF biomedical beamline ID17 is technically ready for the irradi-
ation of deep-seated tumors of cats and dogs in ﬁrst veterinary
trials. The full chain from treatment planning to precise irradiation
including conformal masks has been tested and works properly. A
graphical user interface for easy control of the image-guidance
software is currently under development.
Discussion and conclusions
With the currently ongoing SSRT clinical trials it will be possible
to reﬁne a protocol for dose enhancement using high Z elements in
combination with low-energy SR X-rays. Such an improved proto-
col can on one hand possibly be exploited at the clinics using higher
photon energies and on the other hand be combined later with
clinical trials in MRT with a reﬁned protocol for drug delivery to
combine the synergetic effects in one single novel radiation therapy
approach.
With the veterinary trials currently underway in MRT, the
treatment of deep seated tumors with spatially fractionated low
energy photons in pets is challenging due to the presence of thick
bone structures. The gain from conformal image guided MRT
treatment in the near future using 3 multiple ports will provide an
initial ﬁrst geometrical improvement, which can soon be handled
from a technical and safety point of view. Further steps may be
necessary to increase the TCP while reducing possible normal tis-
sue complications. With increasingly complex irradiation modal-
ities, the challenges on high precision dose measurements within
microscopically small movements represent an important step to
deﬁne a safe treatment strategy with optimized dose delivery and ahigh therapeutic index. It should be kept in mind that the demands
on the Medical Physics developments may be beyond the current
technology available and potential additional uncertainties in dose
delivery can be handled by a lower peak entrance dose to copewith
the lacking accuracy to make the treatment safe. The therapeutic
gain using spatially fractionated beams to exploit the dose volume
effect and efﬁciently reduce tumor volume by introducing a pref-
erential damage on the tumor vasculature should nevertheless be
visible, even when peak entrance dose values include additional
safety margins.
A number of other applications using microbeams are now
emerging, including the treatment of epilepsy, Parkinson's disease
or chronic pain, and it is worth pointing out that the Medical
Physics aspects relating to dosimetry and the design of the TPS are
identical for these studies, too. In the presence of respiratory mo-
tion and cardiac pulsatility, it may perhaps never be possible to
achieve the precision required for the complete joining of inter-
laced microbeams in larger targets, as would be needed to translate
some of the more advanced approaches to treat humans safely.
Nevertheless, there is much scope for important technical de-
velopments in the years to come, whilst, at present, the more exotic
applications are instead using the microbeams as a research tool to
improve our understanding of the underlying mechanisms. Similar
considerations apply to the applications of larger “microbeams”,
often also referred to as minibeams, but in this case, much of the
biological data is, as yet, largely missing. Over the past 25 years a
vast amount of experience in MRT, together with preclinical data,
have been accumulated and for this reason we believe that we are
justiﬁed in our claim that MRT has matured into a technique to be
promoted soon for clinical trials.
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